I also think it likely Merck are watching with some interest but perhaps not as intently as we would like. We should be reminded that Imugene are purchasing and supplying Keytruda independently of them, probably the same as a plethora of other biotech companies wanting to trial with them. Unfortunately, (or perhaps fortunately?) having a supply agreement in place with them for the vaxxinia trial meant things were going to move to slow for what Imugene had in mind for the trials which is why they opted for the independent path. I think this adds some weight as to the speed Imugene are moving through the trials at.
IMU Price at posting:
4.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)